ConvaTec Group (CTEC) Share Price, News & Analysis

Company Overview

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 227.20 to 233.80
• 50-Day Range: 200 to 236
• 52-Week Range: 193 to 259.30
• Volume: 10.12 million shs
• Average Volume: 39.98 million shs
• Market Capitalization: £4.49 billion
• P/E Ratio: 26.70
• Dividend Yield: 2.37%
• Price Target: GBX 306
• Consensus Rating: Moderate Buy

ConvaTec Group Stock Analysis - MarketRank™

ConvaTec Group scored higher than 98% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ConvaTec Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

ConvaTec Group has a consensus price target of GBX 306, representing about 33.3% upside from its current price of GBX 229.60.

Amount of Analyst Coverage

ConvaTec Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ConvaTec Group is 26.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of ConvaTec Group is 26.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.81.

Price to Earnings Growth Ratio

ConvaTec Group has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

ConvaTec Group has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CTEC.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

ConvaTec Group pays a meaningful dividend of 2.37%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

ConvaTec Group does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of ConvaTec Group is 78.71%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.89

News Sentiment

ConvaTec Group has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ConvaTec Group this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added ConvaTec Group to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of ConvaTec Group in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net £213,500 in company stock, which represents 0.0048% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, ConvaTec Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought £213,500 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

0.98% of the stock of ConvaTec Group is held by insiders.

Percentage Held by Institutions

68.35% of the stock of ConvaTec Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/28/2020
• Today: 8/14/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:CTEC
• CIK: N/A
• Web: www.convatecgroup.com
• Phone: 44 11 8952 8100
• Fax: N/A
• Employees: 10,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ConvaTec Group: GBX 306
• High Price Target: GBX 375
• Low Price Target: GBX 230
• Potential Upside/Downside: +33.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 8.60
• Trailing P/E Ratio: 26.70
• Forward P/E Ratio: 16.94
• P/E Growth: 0.93
• Net Income: £188.35 million
• Net Margins: 4.99%
• Pretax Margin: N/A
• Return on Equity: 8.40%
• Return on Assets: 5.01%

Debt

• Debt-to-Equity Ratio: 121.83
• Current Ratio: 1.93
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: £2.49 billion
• Price / Sales: 1.80
• Cash Flow: GBX 13.50 per share
• Price / Cash Flow: 17.01
• Book Value: GBX 80.01 per share
• Price / Book: 2.87

Miscellaneous

• Outstanding Shares: 1,954,455,000
• Free Float: N/A
• Market Cap: £4.49 billion
• Optionable: Not Optionable
• Beta: 0.77